Nanobiotix (NASDAQ:NBTX) Upgraded to Hold at UBS Group

Nanobiotix (NASDAQ:NBTX) was upgraded by equities research analysts at UBS Group to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Nanobiotix Stock Performance

Shares of NBTX stock opened at $3.95 on Monday. The firm has a fifty day simple moving average of $3.30 and a 200-day simple moving average of $4.15. Nanobiotix has a twelve month low of $2.76 and a twelve month high of $7.51.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new position in Nanobiotix during the 4th quarter valued at $29,000. Millennium Management LLC bought a new position in Nanobiotix during the 4th quarter valued at $39,000. Jane Street Group LLC bought a new position in Nanobiotix during the 4th quarter valued at $73,000. Finally, OLD Mission Capital LLC bought a new position in Nanobiotix during the 4th quarter valued at $139,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.